66 research outputs found
INFLUENZA AVIARIA NELLE SPECIE SELVATICHE IN ITALIA: ECOLOGIA E FATTORI DI RISCHIO
No full textL'ARTICOLO DESCRIVE L'ECOLOGIA DEI VIRUS INFLUENZALI DI TIPO A SOTTO IL PROFILO EVOLUZIONISTICO ED ECOLOGICO. VENGONO EVIDENZIATI I RUOLI DI SERBATOI E DI EPIFENOMENI NELLE POPOLAZIONI NATURALI SIA SELVATICHE SIA DOMESTICHE E NE VENGONO ANALIZZATI I FATTORI DI RISCHIO PER L'UOMO E PER LE PRODUZIONI ANIMALI
Fatigue as a clinical sign of biological aging : exploratory analyses from the MINDED project
No full textImmunohistochemical MHC-II and IL2R (CD25) expression in lymph nodes of pigs with spontaneous post-weaning multisystemic wasting syndrome (PMWS)
No full textImmunohistochemical expression of immunocompetent cells bearing major histocompatibility complex (MHC-II) and interleukin 2-R (IL2-R) (CD25) molecules was performed on lymph nodes with spontaneous postweaning multisystemic wasting syndrome (PMWS). Control lymph nodes displayed intense diffuse immunoreactivity to MHC-II in both follicles and interfollicular areas. A marked reduction of follicular MHC-II immunoreactivity and inconsistent staining of histiocytes in interfollicular areas was observed in PMWS cases with a slight lymphoid depletion; in those cases with moderate to severe lymphoid depletion, there was a progressive decrease in MHC-II expression. In controls and in slightly depleted nodes, IL2-R was equally expressed in interfollicular tissue and in follicles, whereas in moderate and severe cases, it was detected in interfollicular remnants only.
Immunohistochemical staining was scored semiquantitatively. The mean MHC-II score was significantly reduced in PMWS cases compared with controls (Spearman test), whereas there was no difference in the IL2-R score. The evident reduction of MHC-II immunoreactivity suggests an impairment in MHC-II linked antigen presenting cell expression
Il virus A/Mallard/Italy Unibo/167/2007 (H5N1 LPAI) OGGETTO DEL BREVETTO, è depositato presso la Collection Nazionale de Cultures de Microrganismes – Parigi CON IL NUMERO CNCM-T-3875
No full textGli inventori della presente invenzione, nel corso di campionamenti di avifauna selvatica, in un’area palustre della Toscana, hanno sorprendentemente isolato il ceppo oggetto della presente invenzione.
Il ceppo isolato è stato denominato A/Mallard/Italy/Unibo 167/2007 (H5N1 LPAI) ed a questa definizione si farà riferimento in seguito.
Questo virus è caratterizzato dal fatto di possedere un’Emoagglutinina (HA), del sottotipo H5, ed una Neuroaminidasi, del sottotipo N1.
Il sequenziamento parziale del sito di clivaggio dell’Emoagglutinina ha evidenziato l’assenza di aminoacidi basici nelle regioni che caratterizzano i virus altamente patogeni.
I test sierologici di inibizione dell’emoagglutinazione ed i test biomolecolari di RT PCR ne hanno confermato l’appartenenza al sottotipo (HA) H5 ed NA (N1).
Il ceppo isolato presenta il notevole vantaggio di avere una bassa patogenicità, pur essendo del tipo H5.
Il nuovo ceppo isolato è adatto alla preparazione di composizioni farmaceutiche, in particolare sotto forma di vaccini, per uso umano e veterinario, per la prevenzione delle infezioni virali.
Detto ceppo virale è anche adatto alla preparazione di composizioni diagnostiche, in particolare sotto forma di kit, per la determinazione di infezioni virali in fluidi biologici umani e animali.
Inoltre, il suo impiego nella preparazione di vaccini risulta di facile attuazione in quanto non è necessario sottoporlo a modificazione genetica, mediante le tecniche precedentemente menzionate, per renderlo inattivo, in quanto già dotato di un basso livello di patogenicità
Subacute cutaneous lupus erythematosus induction after SARS-CoV-2 vaccine in a patient with primary biliary cholangitis
No full textA 30-year-old Italian woman presented due to the suddenoccurrence of papules and plaques on her face and upper back
BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies
No full textBackground: A number of mutations related to malignant melanoma (MM) have been identified, and of the mutated genes, BRAF has been found to be altered in > 50% of cases. Most of these have been BRAF V600E mutations, whereas the incidence of BRAF V600K may vary from 10% to 30%. Little is known about the clinical prognostic correlations of BRAF V600K MMs. We evaluated the clinical and dermoscopic features, incidence, therapy response and outcomes in the medium to long term. Aim: To compare the clinical and dermoscopic characteristics, the response to systemic therapies and the prognosis among MMs with BRAF V600E and BRAF V600K mutations. Methods: We retrieved the data of patients tested in our centre for MM from 2012 to 2015, including clinical features, dermoscopic pictures, clinical history and tumour mutations. Only patients with BRAF V600E and BRAF V600K mutations were included. Any MMs positive for BRAF V600K mutation were collected, and the number of V600K cases and their features were used to extract the same number of patients with BRAF V600E from our database using a matching method. The clinical and dermoscopic presentation, therapy response and disease progression of the two groups were then evaluated. Results: In total, 132 cases of BRAF V600E-mutated MMs were identified, and then randomized with a propensity-score method to match the 10 retrieved cases of BRAF V600K mutation. Both groups had a nodular appearance to the tumours and an advanced disease stage, and no significant differences in dermoscopic features were highlighted. During the follow-up period, four patients with BRAF V600K died of disease-specific causes. Moreover, we found a higher frequency of metastasis, a faster disease progression and more rapid mortality in patients with BRAF V600K. Conclusion: Despite the small size of this study, the results show similar clinical and dermoscopic characteristics between V600E and V600K mutations, but compared with BRAF V600E MMs, BRAF V600K MMs seem to be less responsive to therapy and have a worse prognosis
Unilateral eosinophilic fasciitis (Shulman syndrome) with excellent response to combined treatment with methotrexate therapy and compression brace
No full textWe report the case of a 78-year-old Caucasian male examined in our dermatological unit for swelling of the right arm. He described an increase in right arm size, which had a slow and progressive growth over the last two years and a perception of skin hardening and difficulty in flexing and extending the joint. Moreover, he has been experiencing muscle pain during the previous eight months. The past medical history accounts for a non-Hodgkin B cell lymphoma marginal type treated ten years before with splenect
Disseminated herpes zoster in an immune-competent patient after SARS-CoV-2 vaccine (BNT162b2 Comirnaty, Pfizer)
No full textn
- …
